Date:
11/7/18
The R4P2018 conference included a wealth of studies looking at broadly neutralising monoclonal antibody (bNAbs) for HIV prevention.
A selection of these studies reported below shows the complexities of this research which is important given large-scale studies are already ongoing.
New data on a long-acting variant of the bNAb VRC01 that requires less frequent infusions was included in several presentations.
This extended release formulation, VRC01-LS, has a two amino acid change that showed more durable protection against repeated SHIV challenges in animal studies.